Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment



Status:Recruiting
Conditions:Cognitive Studies
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:65 - 85
Updated:4/21/2016
Start Date:September 2014
End Date:September 2019
Contact:Salit Tzaban, PhD
Email:salitt@enzymotec.com
Phone:+972-74-7177193

Use our guide to learn which trials are right for you!

A, Multi-center, Double-blind, Randomized, Placebo-controlled Study for the Efficacy of Phosphatidylserine in Mild Cognitive Impairment (MCI)

The primary objective is to evaluate the efficacy and safety of phosphatidylserine (PS) on
cognitive abilities in MCI


Inclusion Criteria:

1. Age greater than or equal to 65 and less than or equal to 85 years.

2. Formal education greater than or equal to 10 years.

3. Male or female with a diagnosis of Mild Cognitive Impairment (MCI) according to
consensus criteria as defined by Petersen.

4. Clinical Dementia Rating Scale score (CDR) ≤0.5.

5. Adequate vision, hearing, and literacy ability to allow for neuropsychological
testing.

6. Able and willing to perform all study procedures.

7. Ability to provide written consent signed by the subject

Exclusion Criteria:

1. Any significant neurological condition or disorder (e.g., seizure disorder, epilepsy,
brain tumors, stroke, etc.) that could cause cognitive deterioration other than
suspected MCI.

2. Any medical condition or disorder that could produce cognitive deterioration (i.e.,
renal, respiratory, cardiac, and hepatic disease, diabetes mellitus, endocrine,
metabolic or hematological disturbances) unless well controlled for at least 3
months.

3. Clinically significant abnormal serum Thyroid-stimulating hormone (TSH) and/or B-12
and/or folic acid levels below the normal range.

4. History of any infective or inflammatory brain disease including viral, fungal or
syphilitic etiologies.

5. Head trauma or injury immediately preceding cognitive deterioration, unless over 2
years have passed since full cognitive and functional recovery.

6. Depression at screening as assessed by Geriatric Depression Scale-short version
(score ≥5)

7. Current suicidality at screening by Columbia Suicidality Severity Rating Scale.

8. Dementia by Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria.

9. Concomitant use of medications and/or dietary supplements with potent psychotropic
properties (antipsychotics, ADHD treatments) or approved for the symptomatic
treatment of dementia due to Alzheimer's Disease (AD) or that affect performance,
e.g., NMDA, acetyl choline esterase inhibitors, antipsychotics, alpha-agonists,
adrenergic blockers, decongestant or sympathomimetic, sedating antihistamines, or
lithium carbonate. Usage of prescription or nonprescription antidepressant agents
with a stable dosage for more than 3 month prior study entry is permitted.

10. Concomitant use of dietary supplements containing DHA, EPA, or phosphatidylserine 8
week prior to the study entry and during the study phase. May be re-screened
following wash-out of 8 weeks.

11. Use of an investigational drug within the last 30 days.

12. Allergic reaction or sensitivity to marine products (fish/seafood) and/or soy.

13. Any known condition which in the opinion of the investigator may be possibly causing
cognitive impairment other than AD (mania, alcohol or substance abuse, mental
retardation, bipolar disorder, panic disorder, obsessive compulsive disorder,
post-traumatic stress disorder, psychotic disorder, major psychiatric disorder
preceding dementia onset or affecting brain function, major surgery ) and/or limits
the successful trial completion.
We found this trial at
6
sites
Toms River, New Jersey 08755
?
mi
from
Toms River, NJ
Click here to add this to my saved trials
Allentown, Pennsylvania 18104
Principal Investigator: PAUL Gross, MD
?
mi
from
Allentown, PA
Click here to add this to my saved trials
Eatontown, New Jersey 07724
Principal Investigator: Marc Ornstein, MD
?
mi
from
Eatontown, NJ
Click here to add this to my saved trials
?
mi
from
Haifa,
Click here to add this to my saved trials
New York, New York 10128
Principal Investigator: Kyra Blatt, MD
?
mi
from
New York, NY
Click here to add this to my saved trials
Reading, Pennsylvania
?
mi
from
Reading, PA
Click here to add this to my saved trials